1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Guidelines for management of sinusitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Screening for peripheral arterial disease in primary care |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Dopamine agonists + levodopa: cost effective in Parkinson's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Rofecoxib more cost effective than NSAIDs for osteoarthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Gemifloxacin offers advantages over clarithromycin for AECB |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 7-8
Pamela Hunter,
Preview
|
|
摘要:
Gemifloxacin offers various advantages over clarithromycin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB), according to data reported at the 22nd International Congress of Chemotherapy [Amsterdam, The Netherlands; July 2001]. Gemifloxacin was shown to be more cost effective both from a healthcare system and a societal perspective, and to have overall health outcome benefits. In addition, gemifloxacin produced a superior long-term clinical response in these patients.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Tezosentan beneficial in acute heart failure? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Mixed results with endothelin receptor antagonists in CV disorders |
|
Inpharma Weekly,
Volume &NA;,
Issue 1307,
2001,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
The selective endothelin (ET)Areceptor antagonist darusentan shows benefits in patients with moderate hypertension, according to results of the HEAT-2*trial presented recently at the 23rd Congress of the European Society of Cardiology [Stockholm, Sweden; September 2001]. A dose-dependent reduction in BP was seen after 6 weeks of therapy with darusentan, and importantly, was not accompanied by any change in pulse rate, leading Dr Roumen Nakov from Knoll AG, Germany, to conclude that'selective endothelin A receptor antagonism holds promise as an effective and safe treatment principle for hypertension'.In contrast, disappointing data were seen with the dual ETAand ETBreceptor antagonist tezosentan in patients with acute heart failure (HF) in the RITZ-1*study. No significant improvements in dyspnoea were seen, compared with placebo, and there was also an increase in adverse events in patients who received tezosentan.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|